An early and non-invasive method for assessing the risk of a subject with pancreatic ductal adenocarcinoma and a method of treating such a disease

摘要

The present invention is a method for non-invasive diagnosis of pancreatic ductal adenocarcinoma (PDAC) in a subject, comprising the step of measuring βig-h3 protein levels in a blood sample, wherein serum βig-h3 levels are at risk of having PDAC. And non-invasive diagnostic methods that correlate positively with The follow-up study of PDAC patients with two different cohorts of 20 and 104 PDAC patients and the PDAC mouse model allows us to detect βig-h3 directly in blood samples, and in tumorigenesis of pancreatic neoplastic lesions It shows that βig-h3 is expressed very early. The invention also relates to antagonists of βig-h3 protein for use in the treatment of PDAC. We found that βig-h3 binds directly on CD8 + T cells by reducing the activation and cytotoxicity properties. Furthermore, the use of neutralizing βig-h3 antibody in PDAC mouse model reduced tumor growth by enhancing CD8 + T cell anti-tumor response. Thus, neutralization of βig-h3, which acts as a novel immunological checkpoint target in PDAC, allows restoration of beneficial anti-tumor immunity in PDAC.